About CanSino Biologics Inc. Company

The company was founded in 2009 in China. It is an industry-leading high-tech biological products company with the mission of providing solutions for the prevention and treatment of infectious diseases worldwide, focusing on the R&D, production and commercialization of innovative, high-quality, and accessible human vaccines. Cansino Biotech's mission has always been to “provide the world with innovative, high-quality, and accessible vaccines” to achieve the corporate vision of “endless innovation, a world free of diseases”. The company has listed H shares on the main board of the Hong Kong Stock Exchange (stock code 6185.HK) and A shares on the Science and Technology Innovation Board of the Shanghai Stock Exchange (stock code 688185). It is the first “A+H” vaccine stock since the opening of the China Science and Technology Innovation Board. The company is an innovative vaccine enterprise dedicated to the development, production and commercialization of innovative vaccines that meet Chinese and international standards. The marketed products and product pipeline cover the prevention of meningitis, pneumonia, tuberculosis, COVID-19, Ebola virus disease, shingles, tuberculosis, and many other vaccine varieties with high clinical demand. The main products are vaccines that are in high clinical demand for the prevention of meningitis, pneumonia, tuberculosis, COVID-19, Ebola virus disease, shingles, tuberculosis, etc. Corporate honors: National High-tech Enterprise, Tianjin Key Laboratory for Respiratory Bacterial Recombination and Combined Vaccine Enterprises, Nankai University Talent Training Cooperation and Development Base, Tianjin Model Group, etc.